Fodi Christina-Katharina, Schittenhelm Jens, Honegger Jürgen, Castaneda-Vega Salvador Guillermo, Behling Felix
Department of Neurosurgery and Neurotechnology, University Hospital Tübingen, Eberhard-Karls University, 72076 Tübingen, Germany.
Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University, 72076 Tübingen, Germany.
J Clin Med. 2022 Apr 23;11(9):2364. doi: 10.3390/jcm11092364.
Meningiomas are the most common primary intracranial tumors. The majority of patients can be cured by surgery, or tumor growth can be stabilized by radiation. However, the management of recurrent and more aggressive tumors remains difficult because no established alternative treatment options exist. Therefore, innovative therapeutic approaches are needed. Studies have shown that meningiomas express somatostatin receptors. It is well known from treating neuroendocrine tumors that peptide radioreceptor therapy that targets somatostatin receptors can be effective. As yet, this therapy has been used for treating meningiomas only within individual curative trials. However, small case series and studies have demonstrated stabilization of the disease. Therefore, we see potential for optimizing this therapeutic option through the development of new substances and specific adaptations to the different meningioma subtypes. The current review provides an overview of this topic.
脑膜瘤是最常见的原发性颅内肿瘤。大多数患者可通过手术治愈，或通过放疗稳定肿瘤生长。然而，复发性和侵袭性更强的肿瘤的治疗仍然困难，因为目前尚无既定的替代治疗方案。因此，需要创新的治疗方法。研究表明，脑膜瘤表达生长抑素受体。从治疗神经内分泌肿瘤中可知，靶向生长抑素受体的肽放射性受体疗法可能有效。迄今为止，这种疗法仅在个别治愈性试验中用于治疗脑膜瘤。然而，小病例系列和研究已证明病情得到稳定。因此，我们认为通过开发新物质并针对不同的脑膜瘤亚型进行特异性调整，有可能优化这种治疗选择。本综述提供了该主题的概述。
